1484 related articles for article (PubMed ID: 32892147)
1. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
2. Biological and pharmacological roles of m
Liu Z; Zou H; Dang Q; Xu H; Liu L; Zhang Y; Lv J; Li H; Zhou Z; Han X
Mol Cancer; 2022 Dec; 21(1):220. PubMed ID: 36517820
[TBL] [Abstract][Full Text] [Related]
3. RNA N
Zhang Z; Zhang C; Luo Y; Zhang G; Wu P; Sun N; He J
Clin Transl Med; 2021 Sep; 11(9):e525. PubMed ID: 34586737
[TBL] [Abstract][Full Text] [Related]
4. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
5. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer.
Liang Z; Kidwell RL; Deng H; Xie Q
Cancer Biol Med; 2020 Feb; 17(1):9-19. PubMed ID: 32296573
[TBL] [Abstract][Full Text] [Related]
7. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
8. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Roles of RNA m
Lan Q; Liu PY; Bell JL; Wang JY; Hüttelmaier S; Zhang XD; Zhang L; Liu T
Cancer Res; 2021 Jul; 81(13):3431-3440. PubMed ID: 34228629
[TBL] [Abstract][Full Text] [Related]
10. TRAIL of Hope Meeting Resistance in Cancer.
Deng D; Shah K
Trends Cancer; 2020 Dec; 6(12):989-1001. PubMed ID: 32718904
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
12. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
14. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.
Shen S; Faouzi S; Bastide A; Martineau S; Malka-Mahieu H; Fu Y; Sun X; Mateus C; Routier E; Roy S; Desaubry L; André F; Eggermont A; David A; Scoazec JY; Vagner S; Robert C
Nat Commun; 2019 Dec; 10(1):5713. PubMed ID: 31844050
[TBL] [Abstract][Full Text] [Related]
15. Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR.
Mohammad IS; He W; Yin L
Crit Rev Ther Drug Carrier Syst; 2020; 37(5):473-509. PubMed ID: 33389848
[TBL] [Abstract][Full Text] [Related]
16. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.
Lin H; Wang Y; Wang P; Long F; Wang T
Mol Cancer; 2022 Jul; 21(1):148. PubMed ID: 35843942
[TBL] [Abstract][Full Text] [Related]
17. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
19. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
[TBL] [Abstract][Full Text] [Related]
20. The detection and functions of RNA modification m
Zhang W; Qian Y; Jia G
J Biol Chem; 2021 Aug; 297(2):100973. PubMed ID: 34280435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
